Exploring vascular dysfunction caused by tirapazamine

Microvascular Research

Volumn 75, Issue 2, 2008, Pages 247-255

  Huxham, Lynsey A ^a   Kyle, Alastair H ^a   Baker, Jennifer H E ^a   McNicol, Krista L ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Carbogen; HCT 116; NOS; SCCVII; SiHa; Tirapazamine; Tubulin; Vasculature

Indexed keywords

CARBOGEN; COMBRETASTATIN A4 PHOSPHATE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TIRAPAZAMINE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROTUBULE; MOUSE; NECROSIS; NONHUMAN; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; TISSUE PERFUSION; VASOCONSTRICTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON DIOXIDE; CELL HYPOXIA; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED NOD; MICE, SCID; NECROSIS; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE SYNTHASE; NITROARGININE; OXYGEN; REGIONAL BLOOD FLOW; TIME FACTORS; TRIAZINES;

MURINAE; MUS;

EID: 39049107800     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2007.09.006     Document Type: Article

References (35)

1. Andrade S.P., Hart I.R., and Piper P.J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 107 (1992) 1092-1095
2. Baguley B.C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4 (2003) 141-148
3. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8 (2002) 1974-1983
4. Brown J.M., and Lemmon M.J. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol. 20 Suppl 1 (1991) 151-156
5. Butler S.A., Wood P.J., Cole S., et al. Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br. J. Cancer 76 (1997) 438-444
6. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 47 (1987) 597-601
7. Chen B., Pogue B.W., Hoopes P.J., et al. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr. 16 (2006) 279-305
8. Cullis E.R., Kalber T.L., Ashton S.E., et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc. Res. 71 (2006) 76-84
9. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57 (1997) 1829-1834
10. Davis P.D., Tozer G.M., Naylor M.A., et al. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1532-1536
11. Dewhirst M.W., Ong E.T., Klitzman B., et al. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat. Res. 130 (1992) 171-182
12. Durand R.E., and LePard N.E. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol. 34 (1995) 317-323
13. Garner A.P., Paine M.J., Rodriguez-Crespo I., et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59 (1999) 1929-1934
14. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26 (1953) 638-648
15. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3 (1997) 177-182
16. Horsman M.R., Chaplin D.J., Hill S.A., et al. Effect of nitro-l-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br. J. Cancer., Suppl. 27 (1996) S168-S171
17. Huxham L.A., Kyle A.H., Baker J.H., et al. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 64 (2004) 6537-6541
18. Huxham L.A., Kyle A.H., Baker J.H., et al. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother. Oncol. 78 (2006) 138-145
19. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4 (1997) 3-21
20. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 4 (1998) 655-657
21. Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53 (1993) 3992-3997
22. Korbelik M., Parkins C.S., Shibuya H., et al. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br. J. Cancer 82 (2000) 1835-1843
23. Kyle A.H., Huxham L.A., Chiam A.S., et al. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res. 64 (2004) 6304-6309
24. Kyle A.H., Huxham L.A., Baker J.H., et al. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumours. Clin. Cancer Res. 13 (2007) 2804-2810
25. Parkins C.S., Dennis M.F., Stratford M.R., et al. Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res. 55 (1995) 6026-6029
26. Parkins C.S., Holder A.L., Hill S.A., et al. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br. J. Cancer 83 (2000) 811-816
27. Raleigh J.A., Dewhirst M.W., and Thrall D.E. Measuring tumor hypoxia. Semin. Radiat. Oncol. 6 (1996) 37-45
28. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 151 (1999) 580-589
29. Ran S., He J., Huang X., et al. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin. Cancer Res. 11 (2005) 1551-1562
30. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
31. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10 (2004) 415-427
32. Tozer G.M., Prise V.E., Wilson J., et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61 (2001) 6413-6422
33. Tozer G.M., Kanthou C., Parkins C.S., et al. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83 (2002) 21-38
34. Vincent L., Kermani P., Young L.M., et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 115 (2005) 2992-3006
35. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin. Cancer Res. 11 (2005) 835-842